227 related articles for article (PubMed ID: 28095720)
1. Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.
Rogowski W; Wachuła E; Lewczuk A; Kolasińska-Ćwikła A; Iżycka-Świeszewska E; Sulżyc-Bielicka V; Ćwikła JB
Future Oncol; 2017 May; 13(12):1069-1079. PubMed ID: 28095720
[TBL] [Abstract][Full Text] [Related]
2. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
[TBL] [Abstract][Full Text] [Related]
3. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms: Is It Really Game Over? A Systematic Review and Meta-analysis.
Rossi RE; Ciafardini C; Sciola V; Conte D; Massironi S
Pancreas; 2018; 47(10):1249-1255. PubMed ID: 30325865
[TBL] [Abstract][Full Text] [Related]
5. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
[TBL] [Abstract][Full Text] [Related]
6. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours.
Rehfeld JF; Broedbaek K; Goetze JP; Knigge U; Hilsted LM
Scand J Gastroenterol; 2020 May; 55(5):565-573. PubMed ID: 32352887
[No Abstract] [Full Text] [Related]
7. Regular chromogranin A monitoring facilitated the early detection of a gastrointestinal neuroendocrine tumour in a patient with type 1 diabetes.
Herold Z; Uhlyarik A; Herold M; Nagy P; Huszty GD; Rosta K; Doleschall M; Somogyi A
Endokrynol Pol; 2020; 71(5):483-484. PubMed ID: 32856287
[TBL] [Abstract][Full Text] [Related]
8. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
[TBL] [Abstract][Full Text] [Related]
9. Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors.
Hauck L; Bitzer M; Malek N; Plentz RR
Scand J Gastroenterol; 2016 Jan; 51(1):55-9. PubMed ID: 26137871
[TBL] [Abstract][Full Text] [Related]
10. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
[TBL] [Abstract][Full Text] [Related]
11. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
12. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
14. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
15. The Role of the Acute Octreotide Suppression Test in Detecting Patients with Neuroendocrine Neoplasms.
Kruljac I; Vičić I; Blaslov K; Kolak Z; Benković M; Kust D; Ladika Davidović B; Tometić G; Penavić I; Dabelić N; Vazdar L; Pavić T; Vrkljan M
Neuroendocrinology; 2018; 107(3):284-291. PubMed ID: 30114698
[TBL] [Abstract][Full Text] [Related]
16. [Gastroenteropancreatic neuroendocrine tumors : targeted diagnostics and therapy].
Holzer K
Chirurg; 2014 Aug; 85(8):731-44. PubMed ID: 25103842
[TBL] [Abstract][Full Text] [Related]
17. Cell-Free DNA and Clinical Characteristics in Patients with Small Intestinal or Pancreatic Neuroendocrine Tumors.
Oversoe SK; Sorensen BS; Tabaksblat EM; Gronbaek H; Kelsen J
Neuroendocrinology; 2022; 112(1):43-50. PubMed ID: 33461190
[TBL] [Abstract][Full Text] [Related]
18. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.
Prinzi N; Raimondi A; Maccauro M; Milione M; Garanzini E; Torchio M; Corti F; Nichetti F; Lo Russo G; Giacomelli L; Mazzaferro V; Di Bartolomeo M; Seregni E; de Braud F; Pusceddu S
Future Oncol; 2019 Sep; 15(26):3015-3024. PubMed ID: 31424273
[No Abstract] [Full Text] [Related]
20. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas.
Pavel ME; Hassler G; Baum U; Hahn EG; Lohmann T; Schuppan D
Clin Endocrinol (Oxf); 2005 Apr; 62(4):434-43. PubMed ID: 15807874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]